Welcome to our dedicated page for BioLife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on BioLife Solutions stock.
BioLife Solutions Inc. (NASDAQ: BLFS), headquartered in Bothell, WA, is a frontline developer, manufacturer, and marketer in the healthcare sector. The company specializes in proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media. Additionally, BioLife Solutions offers a cloud-hosted biologistics cold chain management application for smart shippers.
The company’s primary offerings include the CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® series of automated, water-free thawing devices, the evo® cold chain management system, high-capacity cryogenic storage freezers, and products from acquired entities such as Stirling Ultracold mechanical freezers and SciSafe biologic storage services.
BioLife Solutions has recently announced strategic advancements, including the divestiture of Stirling Ultracold and Custom Biogenic Systems (CBS) freezer assets by December 31, 2023. This move is expected to optimize their product portfolio and focus on higher-margin, recurring revenue streams. Mike Rice, Chairman and CEO, emphasized the commitment to starting 2024 without the freezer product lines, indicating potential for higher shareholder value.
Financially, BioLife Solutions reported updated revenue guidance for 2023 ranging from $144 million to $158 million, and with positive adjusted EBITDA growth expected for 2024. They have also completed notable transactions such as the divestiture of Global Cooling, Inc., which is anticipated to enhance financial performance by reducing operational costs.
Other recent milestones include the introduction of the CryoCase, an innovative cryo-compatible rigid container designed for closed-system fill and retrieval, expected to be available in August 2024. Early evaluations show promising results in cell viability and reduction of particulates, underscoring BioLife’s commitment to innovation in the biopreservation market.
For those interested in the broader financial health and operational developments, BioLife Solutions regularly provides updates through its earnings calls and investor relations webpage.
BioLife Solutions reported Q1 2022 revenue of $36.2 million, a 115% increase year-over-year, driven by 45% organic growth and 53% growth in biopreservation media revenue. The company reaffirmed 2022 revenue guidance between $159.5 million and $171.0 million, expecting year-over-year growth of 34% to 44%. Despite supply chain challenges affecting freezer orders, management expressed confidence in achieving continued growth. The company noted a gross margin of 29% and an adjusted EBITDA loss of $814,000, while also highlighting management's decision to accept stock compensation as a sign of confidence.
BioLife Solutions (NASDAQ: BLFS) will release its first quarter 2022 financial results after the market closes on May 9, 2022. A conference call will follow at 4:30 PM ET, where management will discuss financials and provide a business update. BioLife Solutions is recognized for its innovative bioproduction tools and services tailored for the cell and gene therapy sectors. To access the call, visit their Investor Relations page or dial in at (877) 270-2148 domestically.
BioLife Solutions, Inc. (Nasdaq: BLFS) announced the approval of Grant Thornton LLP as its new independent registered public accounting firm, effective April 6, 2022. This decision comes after the Audit Committee dismissed its previous auditor following a proposal process for the fiscal year ending December 31, 2022. The company filed a Form 8-K detailing these changes, indicating a strategic move to bolster its financial oversight as it continues to provide innovative bioproduction solutions for the cell and gene therapy markets.
BioLife Solutions (Nasdaq: BLFS) announced it received a notice from Nasdaq for failing to timely file its Annual Report on Form 10-K for the year ended December 31, 2021. The notice indicates non-compliance with Nasdaq's listing rules. BioLife's CFO, Troy Wichterman, stated that they intend to file the Form 10-K by March 31, 2022, which may help regain compliance. The company has 60 days from the notice to submit a compliance plan, with a potential extension of up to 180 days if accepted. However, there is no guarantee that Nasdaq will accept the plan.
BioLife Solutions, Inc. (Nasdaq: BLFS) announced an additional delay in filing its Annual Report on Form 10-K for the year ended December 31, 2021. The CFO, Troy Wichterman, stated that they are working diligently to complete the report, aiming to file it by March 31, 2022. This delay raises concerns about compliance with regulatory obligations. BioLife Solutions specializes in bioproduction products and services for cell and gene therapies and broader biopharma markets.
BioLife Solutions (BLFS) has announced growth expectations for its SciSafe biostorage services platform, highlighting the booming outsourced biostorage market. Three key growth catalysts include securing new long-term contracts with East coast and Mid-Atlantic clinical centers, plans to open a new US-based biorepository, and a co-marketing agreement with a research institute. The global biostorage services market is projected to grow from $428 million in 2021 to $900 million by 2029. Revenue guidance for 2022 is set between $159.5 million and $171 million, reflecting strong year-over-year growth.
BioLife Solutions, a key player in bioproduction for cell and gene therapies, has announced that its leadership team, including CEO Mike Rice, COO Rod de Greef, and CFO Troy Wichterman, will present at two major investor conferences in March 2022. The first is the Cowen 42nd Annual Health Care Conference on March 9, and the second is the KeyBanc Life Sciences & MedTech Forum on March 23. These events will showcase BioLife's innovations and strategies in the biopharma market.
BioLife Solutions (BLFS) reported strong financial results for Q4 and full year 2021, achieving a record revenue of $37.3 million in Q4, up 153% year-over-year, and $119.2 million for the year, a 148% increase. The company expects 2022 revenue guidance between $159.5 million and $171 million, reflecting a growth of 34% to 44%. Key drivers include increased customer acquisition and demand for biopreservation media. However, gross margins declined significantly due to product mix and operational issues following recent acquisitions.
BioLife Solutions, Inc. (NASDAQ: BLFS) will release its fourth quarter and full year 2021 financial results after market close on February 28. A conference call will follow at 4:30pm ET to discuss the financial results and provide a business update. Investors can access the webcast on the company's Investor Relations page. BioLife Solutions specializes in bioproduction tools and services for cell and gene therapy and broader biopharma markets.
BioLife Solutions (BLFS) reported preliminary revenue results for Q4 and FY 2021, indicating significant growth. Q4 revenue reached $37.3 million, up 153% from $14.7 million in Q4 2020. The total FY 2021 revenue was $119.1 million, a 148% increase from FY 2020's $48.1 million. Key contributors included an 81% growth in Cell Processing and a 389% rise in Storage & Services. Organic revenue rose 64% in Q4 and 37% for the year. CEO Mike Rice expressed optimism for continued growth in 2022, supported by strong demand and successful integration of recent acquisitions.
FAQ
What is the current stock price of BioLife Solutions (BLFS)?
What is the market cap of BioLife Solutions (BLFS)?
What does BioLife Solutions Inc. specialize in?
Where is BioLife Solutions Inc. headquartered?
What are some key products offered by BioLife Solutions?
What recent strategic changes has BioLife Solutions made?
What financial guidance has BioLife Solutions provided for 2023?
What is the CryoCase and when will it be available?
How does BioLife Solutions ensure the safety and efficacy of its products?
How does the divestiture of freezer assets benefit BioLife Solutions?
What are BioLife Solutions' key markets?
Where can investors find more information about BioLife Solutions?
